L & S Advisors Inc Increases Investment in Boston Scientific Co.

L & S Advisors Inc has increased its investment in Boston Scientific Co. (NYSE:BSX) by 21.1% during the fourth quarter, as disclosed in their latest 13F filing with the SEC. This move brought their total shares to 98,710, following the acquisition of an additional 17,191 shares within the quarter.

Boston Scientific represents approximately 1.0% of L & S Advisors Inc's overall investment portfolio, positioning it as the fund’s 26th largest holding. As of the end of the last quarter, these shares were valued at about $8,817,000.

Additional Institutional Investments

Several other investment firms have also engaged in trading Boston Scientific shares recently. For instance, Parnassus Investments LLC increased its holdings by 0.7%, now owning 14,861 shares valued at $1,327,000 after adding 97 shares. PDS Planning Inc raised its stake by 1.5%, accumulating 7,474 shares worth $668,000 after acquiring 113 additional shares.

Adero Partners LLC, Grove Bank & Trust, and PFG Investments LLC also reported increases in their positions in Boston Scientific during the fourth quarter. Overall, institutional investors and hedge funds hold 89.07% of the company's stock.

Stock Performance

As of the last trading session, shares of Boston Scientific opened at $99.29, reflecting a decline of 1.5%. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08, and a quick ratio of 1.02. Its trading performance over the past fifty days shows a moving average of $102.16, while the two-hundred day moving average is $93.04. Over the past year, the stock has fluctuated between a low of $66.80 and a high of $107.17, with a market capitalization of $146.86 billion.

Recent Earnings and Forecasts

Boston Scientific reported its latest earnings results on February 5th, revealing an earnings per share (EPS) of $0.70, exceeding analysts' expectations of $0.65 by $0.05. The company recorded a net margin of 11.07% and a return on equity of 17.80%. Analysts predict that Boston Scientific will achieve an EPS of 2.85 for the current year.

Insider Transactions

In related news, EVP John Bradley Sorenson recently sold 1,201 shares of the company, receiving approximately $127,678.31 from the sale. This represented a decrease of 4.51% in his holdings, which now total 25,443 shares valued at around $2.7 million. Additionally, EVP Arthur C. Butcher sold 17,313 shares for about $1.76 million, resulting in a significant reduction in his ownership.

Analyst Ratings

Several analysts have been closely watching Boston Scientific's stock. Wells Fargo & Company recently raised their price target for the stock from $100 to $118, while Barclays also elevated their target to $118. Alongside these upgrades, Argus set a price objective of $130 for the company’s stock. Overall, 21 analysts rated the stock as a buy, indicating strong investor interest.

About Boston Scientific

Boston Scientific Corporation is involved in the development, manufacturing, and marketing of medical devices tailored for various interventional medical specialties. Spanning two major segments, MedSurg and Cardiovascular, the company provides a range of devices for treating conditions in gastrointestinal, pulmonary, urological, and neurological fields, amongst others.

investment, stocks, medical